Mouden K, Semmar A, Rahali L, Kebdani T, Elkacemi H, Majjaoui S and Benjaafar N
Purpose: The aim of our study is to evaluate the outcome and prognostic factors of triple negative breast cancers in our own experience and we give a critical analysis and an overview of the current prognostic from other institutions.
Materials and methods: One hundred and forty-two patients were evaluated who presented to National Institute of Oncology of Rabat with triple negative breast cancers between January 2010 and December 2010. They were retrospectively analyzed. All patients had invasive breast carcinoma and distribution of stage was 19%, 49.3%, 11.2% and 20.5% for T1, T2, T3 and T4, respectively. Treatment consisted in a mastectomy or conservative surgery with lymphadenectomy, chemotherapy and adjuvant radiotherapy. Overall survival (OS) and relapse-free survival (DFS) were calculated using Kaplan Meier method.
Results: Median age was 48 years (range: 27-86 years). Postmenopausal women presented 47.2% of cases. With a median follow-up of 24.5 months (10-60 months), the rate of local control was 59.9%. We found 18 (12.7%) local relapses, 26 (18.3%) distant relapses. At 5 years, Overall survival(OS), Relapse free survival (RFS) were 61.7% and 53.2% respectively.
Conclusion: Our results emphasize that triple negative breast cancers have a worse prognosis and tend to relapse early which is consistent with other studies.
Share this article
Cancer Science & Therapy received 5332 citations as per Google Scholar report
